Pharvaris (PHVS): The $300M Biotech that Could Be the Next Big Thing in Pharma
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel oral therapies for patients suffering from hereditary…
Abeona Therapeutics (ABEO) s Set to Breakeven—And Analysts Say It’s Just the Beginning
Abeona Therapeutics Inc. (NASDAQ:ABEO) is a clinical-stage biopharmaceutical company pioneering gene and cell therapies aimed at treating rare…
Vigil Neuroscience (VIGL): The Tiny Biotech Sanofi Just Bet $600M On
Vigil Neuroscience Inc. is a clinical-stage biotechnology company pioneering a new approach to treating neurodegenerative diseases by focusing…
Agios (AGIO) Could Explode in 2025—And It’s Not Just Hype
Agios Pharmaceuticals Inc. is a pioneering biotechnology company headquartered in Cambridge, Massachusetts, that has become synonymous with cellular-metabolism…
Hinge Health (HNGE) IPO’d Big—But It’s Just Getting Started
Hinge Health, Inc. is a pioneering digital health company transforming the landscape of musculoskeletal (MSK) care through its…
Warren Buffett Missed This One: Why Johnson & Johnson (JNJ) May Be the Best Buy He Never Made
Johnson & Johnson was founded in 1886 by brothers Robert, James Wood, and Edward Mead Johnson in New…
Buy the Dip? Molina Healthcare (MOH) Just Hit a 52-Week Low—and the Upside Is Stunning
Molina Healthcare Inc. (NYSE:MOH) traces its origins to 1980, when emergency-room physician Dr. C. David Molina opened a…
Buy the Biotech Blue-Chip Before the Surge: Why Amgen (AMGN) Could Soar in 2025
Amgen Inc. (NASDAQ:AMGN) began life in 1980 in a small suite of offices in Thousand Oaks, California, under…
Rigel Pharmaceuticals (RIGL) is Quietly Building a Biotech Empire
Rigel Pharmaceuticals (NASDAQ:RIGL) has quietly emerged as one of the most compelling under-the-radar biotech turnaround stories in the…
Wall Street’s Best-Kept Biotech Secret? Why Pharvaris (PHVS) Could Be the Next $3 Billion Breakout
Pharvaris NV is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, that is redefining the future of…
Is Candel Therapeutics (CADL) the Next Big Cancer Stock? Analysts Say Yes—And It’s Still Cheap
Candel Therapeutics Inc. (NASDAQ:CADL) is a Massachusetts-based clinical-stage immuno-oncology company that traces its roots to pioneering gene-therapy research…
This Tiny Biotech Just Spiked 239%—Here’s Why BioNexus (BGLC) Could Go Even Higher
BioNexus Gene Lab Corp. (NASDAQ:BGLC) is a Malaysia-based, Wyoming-incorporated biotech that has evolved from a niche molecular-diagnostics start-up…
Forget the Headlines — Anavex (AVXL)’s Alzheimer’s Drug Could Change Everything
Anavex Life Sciences Corporation (NASDAQ:AVXL), is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for…
From Penny Stock to Powerhouse? AIM ImmunoTech (AIM)’s Comeback Could Be Epic
AIM ImmunoTech Inc. (NYSE:AIM) traces its roots to 1966, when the company—then known as Hemispherx Biopharma—set out to…
GlaxoSmithKline (GSK)’s Reinvention is Complete—Will This Drug Giant Deliver 50% Upside in 2025?
GlaxoSmithKline plc (NYSE:GSK), commonly referred to as GSK, is a global biopharmaceutical powerhouse headquartered in the United Kingdom…
Abeona (ABEO) Could Be Wall Street’s Next Biotech Darling
Abeona Therapeutics Inc. (NASDAQ:ABEO) is a commercial-stage biopharmaceutical company pioneering the development of gene and cell therapies for…
Pelthos Therapeutics (PTHS): Zero Debt, $50M in Cash, and an FDA Greenlight—What’s Not to Love?
Pelthos Therapeutics Inc. (NYSE:PTHS) is a newly minted, revenue-ready biopharmaceutical company that sprang to life on July 2,…
Biotech Bargain Alert: Theravance Biopharma (TBPH) May Offer Triple-Digit Upside in 2025
Theravance Biopharma Inc. (NASDAQ:TBPH) is a clinical-stage biopharmaceutical company that has steadily built a reputation for its focus…